Nemaura Medical to Present at the Access to Giving Virtual Investor Conference on July 13, 2021
Loughborough, England, July 12, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical (Nasdaq: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 – 15, 2021.
Dr. Chowdhury will deliver his corporate presentation on July 13 at 1:00pm ET.
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email firstname.lastname@example.org.
Investors can register here.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.